改善肝癌预后 关注背景治疗.pptVIP

改善肝癌预后 关注背景治疗 山西医科大学 李玲玲 目录 肝炎/肝硬化是肝细胞癌的重要危险因素 合并肝炎/肝硬化对肝细胞癌预后的影响 肝细胞癌合并肝炎/肝硬化的治疗 The relationship of Hepatitis/Cirrhosis/HCC The influence of coexisting Hepatitis/Cirrhosis on HCC Outcome The principle of HCC patients with Hepatitis/Cirrhosis management 肝炎/肝硬化是肝细胞癌的重要危险因素 Part 1 原发性肝细胞癌 (HCC) 是全球第七大常见癌症 全球每年报道600 000例HCC患者，其中亚洲约占78% Hepatocellular carcinoma (HCC) is the seventh most common cancer and third leading cause of cancer-related death in the world according to the Nat. Rev. Gastroenterol. Hepatol. 7, 448–458 (2010); published online 13 July 2010 亚洲 欧洲 大洋洲 非洲 拉丁美洲和地中海区域 南美 GloboCan 2008 report. Hepatocellular carcinoma (HCC) is the 7th most common cancer Asian countries account for nearly 78% of the roughly 600 000 cases of hepatocellular carcinoma (HCC) reported globally each year. Maps were generated using incidence rates of liver cancer from GLOBOCAN 2002 全球78%的HCC归因于HBV/HCV感染 Perz JF, Armstrong GL, Farrington LA, et al. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol 2006;45:529-538. 57% of cirrhosis was attributable to either HBV (30%) or HCV (27%) and 78% of HCC was attributable to HBV (53%) or HCV (25%). The estimated fractions of cirrhosis attributable to HBV infection ranged from 5% (AMR-A) to 57% (WPR-B) (Table 4, Fig. 1). The fractions of cirrhosis attributable to HCV infection ranged from 16% (AFRD/E) to 62% (WPR-A). The attributable fractions of HCC due to HBV or HCV ranged from 16% (AMRA) to 65% (WPR-B) and from 13% (EMR-B) to 66% (WPR-A), respectively. The two viruses together accounted for 50% of HCC in all of the regions; this was also true for cirrhosis in 8 of 11 regions. Globally, we estimated that approximately 57% of cirrhosis was due to either HBV (30%) or HCV (27%) (Table 4). For HCC, approximately three-quarters (78%) was attributable to HBV (53%) or HCV (25%). Hepatol 2006;